Could a malaria drug help kids with a rare kidney disease?
NCT ID NCT04937907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether hydroxychloroquine, a drug used for malaria and autoimmune conditions, can safely reduce blood and protein in the urine of children with X-linked Alport syndrome, a genetic kidney disease. Fifty children aged 3 to 18 with stable kidney function took the drug for 48 weeks. The goal was to see if it could help control kidney damage, not cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Children's Hospital
Shanghai, Shanghai Municipality, 200062, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- New drug aims to plug kidney leaks in multiple diseases
- Study links gum health to rare kidney diseases
- Alport patients needed: join a registry to speed up research
- Kidney hope: drug combo may slow alport disease
- New drug aims to slow kidney damage in rare alport syndrome